These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 2523157)

  • 1. Reactivity of patient antisera to OKT3 with a panel of CD3 monoclonal antibodies.
    Nashan B; Schwinzer R; Wonigeit K; Pichlmayr R
    Transplant Proc; 1989 Feb; 21(1 Pt 1):985-6. PubMed ID: 2523157
    [No Abstract]   [Full Text] [Related]  

  • 2. The human antimouse reaction to OKT3: cross-reactive pattern analysis using a large group of anti-CD3 and isotypic monoclonal antibodies.
    Shield CF; Hughes JD; Marlett P; Norman DJ
    Transplant Proc; 1989 Feb; 21(1 Pt 1):981-4. PubMed ID: 2523156
    [No Abstract]   [Full Text] [Related]  

  • 3. An overview of the use of the monoclonal antibody OKT3 in renal transplantation.
    Norman DJ
    Transplant Proc; 1988 Dec; 20(6):1248-52. PubMed ID: 2974204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic monitoring with Orthoclone OKT3 therapy.
    Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
    J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RIV-9: a mouse IgG3 anti-human CD3 monoclonal antibody with strong antigen modulating and T cell eliminating properties.
    Vaessen LM; Kreeftenberg JG; Heyse P; Leerling MF; Baumgartner D; Hendriks GF; Jutte NH; Weimer W
    Transplant Proc; 1989 Feb; 21(1 Pt 1):1026-7. PubMed ID: 2523112
    [No Abstract]   [Full Text] [Related]  

  • 6. Are OKT3 binding sites on T cells modulated or merely converted (blindfolded) by OKT3 during therapy?
    Carreno M; Miller J; Esquenazi V; Milgrom M; Roth D; Fuller L
    Transplant Proc; 1989 Feb; 21(1 Pt 1):987-8. PubMed ID: 2565060
    [No Abstract]   [Full Text] [Related]  

  • 7. Usefulness of CD3 or CD6 anti-T monoclonal antibodies in the treatment of acute corneal graft rejection.
    Ippoliti G; Fronterrè A
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3133-4. PubMed ID: 2523173
    [No Abstract]   [Full Text] [Related]  

  • 8. Kinetics of interleukin 6 during OKT3 treatment in renal allograft recipients.
    Bloemena E; ten Berge IJ; Surachno J; Wilmink JM
    Transplantation; 1990 Aug; 50(2):330-1. PubMed ID: 2143327
    [No Abstract]   [Full Text] [Related]  

  • 9. Acute cellular rejection during effective early prophylactic OKT3 monoclonal antibody treatment after renal transplantation.
    Haak HH; Weening JJ; Rischen-Vos J; Daha MR; van Es LA; van der Woude FJ
    Transplantation; 1989 Aug; 48(2):352-4. PubMed ID: 2526973
    [No Abstract]   [Full Text] [Related]  

  • 10. Fine-needle aspiration cytology during treatment with orthoclone monoclonal antibody OKT3 for acute cellular rejection after renal transplantation.
    Hansen BL; Foged N; Nielsen E; Elbirk A; Rohr N; Svendsen V; Birkeland SA
    Transplant Proc; 1988 Aug; 20(4):626-8. PubMed ID: 2970142
    [No Abstract]   [Full Text] [Related]  

  • 11. Prophylactic use of anti-CD3 monoclonal antibody WT32 in kidney transplantation.
    Frenken LA; Hoitsma AJ; Tax WJ; Koene RA
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1072-3. PubMed ID: 1824887
    [No Abstract]   [Full Text] [Related]  

  • 12. The use of an anti-CD3 priming dose to enhance the immunosuppressive potency of monoclonal and polyclonal T-cell antisera.
    Sherburne CG; Onyekaba CO; Condie RM
    Transplant Proc; 1991 Feb; 23(1 Pt 1):626-9. PubMed ID: 1824996
    [No Abstract]   [Full Text] [Related]  

  • 13. Advantages of F(ab')2 fragments of anti-CD3 monoclonal antibody as compared to whole antibody as immunosuppressive agents in mice.
    Hirsch R; Bluestone JA; Bare CV; Gress RE
    Transplant Proc; 1991 Feb; 23(1 Pt 1):270-1. PubMed ID: 1824981
    [No Abstract]   [Full Text] [Related]  

  • 14. OKT3 for induction immunosuppression in renal transplantation: a comparative study of high versus low doses.
    Norman DJ; Barry JM; Bennett WM; Munson JL; Meyer M; Henell K; Kimball J; Hubert B
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1052-4. PubMed ID: 1846453
    [No Abstract]   [Full Text] [Related]  

  • 15. Suppression of the humoral response to anti-CD3 mAB by pretreatment with anti-CD4 mAB.
    Hirsch R; Chatenoud L; Gress RE; Bach JF; Sachs DH; Bluestone JA
    Transplant Proc; 1989 Feb; 21(1 Pt 1):1015-6. PubMed ID: 2523111
    [No Abstract]   [Full Text] [Related]  

  • 16. In situ antigenic modulation of human graft-infiltrating T cells is induced by OKT3 treatment.
    Caillat-Zucman S; Legendre C; Noel LH; Bach JF; Kreis H; Chatenoud L
    Transplant Proc; 1990 Aug; 22(4):1782. PubMed ID: 2143860
    [No Abstract]   [Full Text] [Related]  

  • 17. The successful use of repeated courses of OKT3 for hepatic allograft rejection using %T3 cells to adjust dose.
    Colonna JO; Millis JM; Martello J; Levy P; Iwaki Y; Brems JJ; Klein AS; Hiatt JR; Busuttil RW
    Transplant Proc; 1989 Feb; 21(1 Pt 2):2247-8. PubMed ID: 2523600
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-Leu2a (anti-CD8) monoclonal antibody therapy: antibody-mediated cell clearance in vivo requires Fc-FcRII interaction.
    Wee SL; Phelan JM; Preffer FI; Colvin RB; Cosimi AB
    Transplant Proc; 1989 Feb; 21(1 Pt 1):117-8. PubMed ID: 2495592
    [No Abstract]   [Full Text] [Related]  

  • 19. OKT3 vs ALG induction therapy in combined pancreas-kidney transplantation.
    Knechtle SJ; Pirsch JD; Groshek M; Reed A; D'Alessandro AM; Kalayoglu M; Belzer FO; Sollinger HW
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1581-2. PubMed ID: 1846478
    [No Abstract]   [Full Text] [Related]  

  • 20. Degree of modulation of cell-surface CD3 by anti-lymphocyte therapies.
    Henell KR; Bakke A; Kenny TA; Kimball JA; Barry JM; Norman DJ
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1070-1. PubMed ID: 1824886
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.